KRAS and neoplasm: It has been reported that in a set of CRC cell lines with oncogenic KRAS-BRAF or ERK5 amplification, ERK5 did not contribute to tumor proliferation and no evidence about the regulation of ERK5 by the mutated KRAS/BRAF signaling was observed [86].